Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape

Journal of B.U.ON.

Volumn 20, Issue 6, 2015, Pages 1635-1639

  Tsiambas, Evangelos ^a,f   Ragos, Vasileios ^b   Lefas, Alicia Y ^c   Georgiannos, Stavros N ^d   Grapsa, Dimitra ^e   Patsouris, Efstratios ^f   Syrigos, Konstantinos ^e  

^a 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d Blue Cross Hospital   (Greece)

^e SOTIRIA GENERAL HOSPITAL   (Greece)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cancer; Chromosome; Gene; Hybridization; Lung

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR; BRAF PROTEIN, HUMAN;

ANEUPLOIDY; ARTICLE; CARCINOGENESIS; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME STRUCTURE; GENE DELETION; HUMAN; IN SITU HYBRIDIZATION; MONOSOMY; NON SMALL CELL LUNG CANCER; NONHUMAN; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYSOMY; PROTEIN EXPRESSION; GENETICS; LUNG TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 7; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84960194356     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Stratton MR, Campbell PJ, Futreall AP The cancer genome. Nature 2009; 458:719-724.
2. Hanahan D, Weinberg RA Hallmarks of cancer: The next generation. Cell 2011; 144:646-674.
3. Schlessinger J. Cell Signaling by Receptor Tyrosine Kinases. Cell 2000; 103:211-225.
4. Polyak K, Haviv I, Campbell IG Co-evolution of tumor cells and their microenvironment. Trends Genet 2009; 25:30-38.
5. Albertson DG, Collins C, McCormick F., Gray JW Chromosome aberrations in solid tumours. Nat Genet 2003; 34:369-376.
6. Khoo C, Rogers TM, Féllowes A. Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. Transi Lung Cancer Res 2015; 4:126-141.
7. Kallionemi A. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science 1992; 258:818-821.
8. Bouffard GG, Idol JR, Braden W et al. A physical map of human chromosome 7: an integrated YAC contig map with average STS spacing of 79 kb. Genome Res 1997; 7:673-692.
9. Hubbard T, Barker D, Britney E et al. The Ensemble genome database project. Nucleic Acids Res 2002; 30:38-41.
10. Mouse Genome Sequencing Consortium. Initial sequencing and comparative analysis of the mouse genome. Nature 2002; 420:520-562.
11. Pruitt KD, Maglott DR RefSeq and LocusLink: NCBI gene-centered resources. Nucleic Acids Res 2001; 29:137-140.
12. Riordan JR, Rommens JM, Kerem B et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066-1073.
13. Liang H, Fairman J, Claxton D.F., Nowell PC, Green ED, Nagarajan L. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. Proc Natl Acad Sci, USA 1998; 95:3781-3785.
14. Korenberg JR, Chen XN, Hirota H et al. Genome structure and cognitive map of Williams syndrome. J Cogn Neurosci 2000; 12:89-107.
15. Yu HA, Riely. GJ, Lovly CM. Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Clin Cancer Res 2014; 20:5898-5907.
16. Luo YH, Chen YM Recent advances in the development of mutant-selective EGFR inhibitors for nonsmall cell lung cancer patients with EGFR-TKI resistance. Transi Lung Cancer Res 2014; 3:368-369.
17. Krishnaswamy S, Kanteti R, Duke-Cohan JS et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009, 15:5714-5723.
18. De Oliveira Duarte Achcar R, Nikiforova MN, Yousem SA. Micropapillary lung adenocarcinoma: EGFR, K ras, and BRAF mutational profile. Am J Clin Pathol 2009; 131:694-700.
19. Kim HR, Cho BC, Shim HS et al. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer 2014; 83:374-382.
20. Hirsch FR, Dziadziuszko R, Thatcher N et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 2008; 112:1114-1121.
21. Ogiso H, Ishitani R, Nureki O et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-787.
22. Yarden Y, Sliwkowski MX Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
23. Sun JM, Ahn MJ, Choi YL et al. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013; 82:294-298.
24. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
25. Gaber R, Watermann I, Kugler C., Reinmuth N. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. Diagn Pathol 2014; 9:165-179.
26. Lee HJ, Xu X, Choe G et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. Lung Cancer 2010; 68:375-382.
27. Hirsch FR, Varella-Garcia M, Cappuzzo F et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007; 18:752-760.
28. Toffalorio F, de Marinis F, Conforti F et al. Erlotinib efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRas wild-type tumors. J Thorac Oncol 2015; 10:392-396.
29. Xiao H, Wang J, Liu Y., Li L. Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer. Oncol Lett 2014; 8:582-588.
30. Furugaki K, Iwai T, Moriya Y., Harada N, Fujimoto-Ouchi K Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EG-FR-TKIs in EGFR-mutated NSCLC cells. Lung Cancer 2014; 83:44-50.
31. Moumen A, Patané S, Porras A, Dono R, Maina F. Met acts on Mdm2 via mTOR to signal cell survival during development. Development 2007; 134:1443-1451.
32. Song L, Rawal B, Nemeth JA et al. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011; 10:481-494.
33. Benedettini E, Sholl LM, Peyton M et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010; 177:415-423.
34. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-1043.
35. Van Der Steen N, Pauwels P, Gil-Bazo I. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers 2015; 7:556-573.
36. Casorzo L, Corigliano M, Ferrero P., Venesio T, Risio M. Evaluation of 7q31 region improves the accuracy of EGFR FISH assay in non small cell lung cancer. Diagn Pathol 2009; 4:4:36-40.
37. Cardarella S, Ogino A, Nishino M et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non small cell lung cancer. Clin Cancer Res 2013; 19:4532-4540.
38. Weir BA, Woo MS, Getz G et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007; 450:893-898.
39. Gautschi O, Pauli C, Srobel K et al. A patient with BRAF V600E lung adenocarcinoma responding to vemufafenib. J Thorac Oncol 2012; 7:e23-e24.
40. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose escalation trial. Lancet 2012; 379:1893-1901.
41. Sasaki H, Maekawa M, Tatematsu T et al. Increased BRAF copy number in lung adenocarcinoma. Oncol Lett 2015; 9:709-712.
42. Varella-Garcia M. Chromosomal and genomic changes in lung cancer. Cell Adhesion Migration 2009; 4:100-106.
43. Matthews LC, Berrya AA, Morgan DJ et al. Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy. PNAS 2015; 112:5479-5484.